Dimatingcal, Monera I.

HRN: 26-55-69  Sex: Female

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
03/20/2025
CEFUROXIME 1.5GM (VIAL)
03/21/2025
03/28/2025
IV
1.5 G
Every 8 Hours
Breast Mass
Waiting Final Action 

Indication:  ProphylaxisEmpiric    Type of Infection:  Skin & Soft Tissue    Compliance to guidelines: Compliant To Guidelines

Initial appropriateness: Yes   

Final appropriateness: Yes   

Overall appropriateness: Yes 

Intervention



Type of Intervention done:

                    

           


Acceptance: